169 related articles for article (PubMed ID: 16389172)
1. Keynote comment: reimbursement for molecularly targeted anticancer agents.
Tirelli U; de Castro G; Awada A
Lancet Oncol; 2006 Jan; 7(1):2-3. PubMed ID: 16389172
[No Abstract] [Full Text] [Related]
2. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
3. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
4. NICE, the NHS, and Cancer Drugs.
Dillon A; Landells LJ
JAMA; 2018 Feb; 319(8):767-768. PubMed ID: 29387883
[No Abstract] [Full Text] [Related]
5. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
6. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
Kim ES; Kim JA; Lee EK
Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
[TBL] [Abstract][Full Text] [Related]
7. Approvals in 2016: questioning the clinical benefit of anticancer therapies.
Booth CM; Del Paggio JC
Nat Rev Clin Oncol; 2017 Feb; 14(3):135-136. PubMed ID: 28218259
[No Abstract] [Full Text] [Related]
8. [Pharmacoeconomics and cost of cancer drugs].
Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
[TBL] [Abstract][Full Text] [Related]
9. When will the U.S. flinch at cancer drug prices?
Vanchieri C
J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
[No Abstract] [Full Text] [Related]
10. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
Navarro RP; Morrow T; Baran R
Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomics in the era of individualized medicine.
Waldman SA; Terzic A
Clin Pharmacol Ther; 2008 Aug; 84(2):179-82. PubMed ID: 18679176
[No Abstract] [Full Text] [Related]
13. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
[No Abstract] [Full Text] [Related]
14. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
Yong JH; Beca J; Hoch JS
Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
[TBL] [Abstract][Full Text] [Related]
15. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
Sobrero A; Bruzzi P
J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
[No Abstract] [Full Text] [Related]
16. Genentech caps cost of cancer drug for some patients.
Pollack A
N Y Times Web; 2006 Oct; ():C2. PubMed ID: 17061339
[No Abstract] [Full Text] [Related]
17. [Economic effects of "molecular" medicine].
Riemann JF
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1740. PubMed ID: 17713881
[No Abstract] [Full Text] [Related]
18. Oncology drug pricing structure is broken.
Hutchinson L
Nat Rev Clin Oncol; 2015 Sep; 12(9):499. PubMed ID: 26309071
[No Abstract] [Full Text] [Related]
19. Grouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis.
Tirelli U; Berretta M; Bearz A; Carbone A
Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1355-6. PubMed ID: 22195374
[No Abstract] [Full Text] [Related]
20. Efficacy, safety, and cost of new anticancer drugs. Price needs to be evaluated against effectiveness.
Messori A; Trippoli S; Vaiani M
BMJ; 2002 Nov; 325(7375):1302; author reply 1302. PubMed ID: 12463189
[No Abstract] [Full Text] [Related]
[Next] [New Search]
